PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes

Author： Qin Ya-Zhen Zhu Hong-Hu Liu Yan-Rong Wang Ya-Zhe Shi Hong-Xia Lai Yue-Yun Xu Lan-Ping Liu Dai-Hong Jiang Qian Li Ling-Di Jiang Bin Liu Kai-Yan Huang Xiao-Jun

Publisher： Informa Healthcare

ISSN： 1042-8194

Source： Leukemia and Lymphoma, Vol.54, Iss.7, 2013-07, pp. : 1442-1449

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression

Experimental and Therapeutic Medicine, Vol. 3, Iss. 1, 2012-01 ,pp. : 129-133

Spandidos Publications

Access to resources Recommend Favorite

Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes

By Ueda Yasunori

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1450-1458

Informa Healthcare

Access to resources Recommend Favorite

Circulating free DNA: a new surrogate marker for minimal residual disease?

By Fehm Tanja

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 119-122

Springer Publishing Company

Access to resources Recommend Favorite

Minimal Residual Disease in Breast Cancer

By Kvalheim G.

Cancer and Metastasis Reviews, Vol. 18, Iss. 1, 1999-01 ,pp. : 101-108

Springer Publishing Company

Access to resources Recommend Favorite

Minimal Residual Disease in Head and Neck Cancer

By Gath H.J.

Cancer and Metastasis Reviews, Vol. 18, Iss. 1, 1999-01 ,pp. : 109-126

Springer Publishing Company

Access to resources Recommend Favorite